Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparative Effectiveness of Elranatamab (PF-06863135) in Clinical Study C1071003 Versus Standard of Care (SOC) in Real-World (RW) External Control Arms in Patients With Triple-Class Refractory (TCR) Multiple Myeloma (MM)

NCT05932290 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05932290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05932290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparative Effectiveness of Elranatamab (PF-06863135) in Clinical Study C1071003 Versus Standard of Care (SOC) in Real-World (RW) External Control Arms in Patients With Triple-Class Refractory (TCR) Multiple Myeloma (MM)
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
June 1, 2023
Completion date
July 12, 2023
Enrollment
514 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma